𝘔𝘌𝘛 Alterations in NSCLC: Applying Diagnostic Advances and Targeted Therapies in a New Era of Treatment

Activity Overview

This online, on-demand virtual symposium brings together renowned experts in non-small cell lung cancer (NSCLC). In this educational program, these experts explore the critical differences between c-Met protein overexpression and MET exon 14 skipping mutations in NSCLC. Faculty delve into the latest therapeutic advancements, including antibody-drug conjugates targeting c-Met and tyrosine kinase inhibitors for MET exon 14 mutations, emphasizing clinical trial data and real-world applications.

This educational activity is an archive of the live presentation held on July 24, 2026.

Target Audience

This educational activity is directed toward medical, surgical, and radiation oncologists interested in the treatment of patients with lung cancer. Fellows, nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other health care professionals interested in the treatment of lung cancer are also invited to attend.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Assess molecular testing strategies for identifying categories of MET alterations in patients with NSCLC
• Apply FDA-approved and investigational c-MET–directed therapies based on the type of MET alteration in patients with advanced NSCLC
• Evaluate emerging clinical evidence for next-generation c-MET–targeting agents and combination strategies in MET-dysregulated NSCLC
• Develop evidence-based approaches to identify and manage adverse events associated with c-MET–directed therapies, including those specific to antibody-drug conjugates

The staff of Physicians’ Education Resource^®, LLC, have no relevant financial relationships with ineligible companies.

PER^® mitigated all conflicts of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This accredited continuing education activity was planned in accordance with the ACCME Standards for Integrity and Independence to ensure balance, objectivity, independence, and scientific rigor. Faculty were instructed to use generic names when possible and to base recommendations on the best available evidence. Proprietary product names may be referenced in clinical discussion for educational purposes only and do not imply endorsement.

This activity may include discussion of investigational, unapproved, or off‑label uses of drugs or devices. Learners are advised to consult prescribing information for products discussed. Content is provided for educational purposes only and is not a substitute for the independent clinical judgment of a health care professional. Learners are encouraged to critically evaluate the information presented and apply their own clinical judgment.

The views expressed are those of the individual faculty members and do not necessarily reflect the views of the accredited provider or any entity providing commercial support.

This activity may have used AI-assisted tools to support educational development. All content was reviewed and approved by qualified faculty or planners. The accredited provider retains full responsibility for accuracy, balance, and independence.